Theialife

Theialife is a virtual innovative late clinical-stage biopharmaceutical company focused on the discovery and development of a first-in-class ophthalmology drugs, including our anchor drug for early-onset paediatric myopia (near-sightedness). ND10 is the first oral therapeutic for the treatment of myopia progression. Post Phase 2 clinical trial in Denmark we have used ND10 in clinical practice for over 15 years, and have treated over 1200 children. Our work is published in the British Journal of Ophthalmology. Myopia is a lifestyle disorder that in the past 15 years has exploded exponentially due to children being exposed early to devices like mobile phones, iPads and computer screens. As a result, children spend less time outdoors in the sun. Myopia is a physical deformity where the eye is elongated more than normal. Once the child reaches age 18 the eye shape is solidified with collagen cross linking and as a result no treatment is possible after age 18 or so. This includes no surgical treatment or therapeutic treatment. Thus, the only way to avoid High Myopia is to prevent Myopia progression one day at a time. This is from the day of first diagnosis to age 18 years. In addition, we have a rich pipeline of preclinical ophthalmology related assets and 3 novel molecules. All IP related to The Dosage Form and related data is owned by Theialife. From the time we filed in 2024, we retain our IP for 20 years. This first-in-class molecule will change the landscape of myopia management. This is especially important for children who otherwise, given the limited therapies available, will progress towards high myopia. This can lead to severe ocular medical issues and even retinal detachment and blindness. We intend to establish our global headquarters in Boston, MA, USA. We are currently exploring commercialization partnerships in specific geographies outside of the USA.